Clinical trials
Advanced Breast Carcinoma clinical trials
Below are recruiting advanced breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 353 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05797805RecruitingPhase 1/Phase 2
Tegavivint for advanced liver cancer after prior treatments
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Duarte, CaliforniaAges 18 years+ - NCT06676982RecruitingPhase 1
CAR-T cell therapy for advanced liver cancer
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
Hangzhou, ZhejiangAges 18–80 - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT06450873RecruitingPhase 2
Turkey tail mushroom before breast cancer surgery
This trial tests whether taking a turkey tail mushroom supplement before breast cancer surgery can help the immune system fight the cancer. It is for post-menopausal women with a common type of breast cancer (ER-positive, HER2-negative) that is growing at a moderate or faster rate (Ki-67 score of 10% or more).
Scottsdale, ArizonaAges 18 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT06151743RecruitingPhase 2
Testing drug combo before throat cancer surgery
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07039201Recruiting
A cell therapy for liver cancer that has progressed on other treatments
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07810088RecruitingPhase 2
Dalpiciclib with hormone therapy and blood pressure drug for advanced breast cancer
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
Wuhan, HubeiAges 18–75 - NCT07478302RecruitingPhase 1
A study of two drugs for untreated advanced liver cancer
This trial tests a combination of two medications, SHR-2524 and bevacizumab, as a first treatment for people with advanced hepatocellular carcinoma (a type of liver cancer) that has not been treated with cancer drugs before. The goal is to see if this combination can help shrink or control the cancer.
Fuzhou, FujianAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT07299409RecruitingPhase 2
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
Vancouver, British ColumbiaAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07036380RecruitingPhase 2
Testing MP0317 with chemotherapy for advanced bile duct cancer
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
BesançonAges 18 years+ - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07221942RecruitingPhase 2
Pembrolizumab and Enfortumab Vedotin for Advanced Bladder Cancer
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+
Hear when a new Advanced Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced breast carcinoma?
- Yes. Clin2 currently lists 353 recruiting advanced breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.